Pathstone Holdings LLC raised its holdings in shares of GSK plc (NYSE:GSK - Free Report) by 12.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 246,614 shares of the pharmaceutical company's stock after purchasing an additional 26,707 shares during the quarter. Pathstone Holdings LLC's holdings in GSK were worth $10,086,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also bought and sold shares of the company. Eastern Bank bought a new position in GSK during the third quarter valued at $26,000. Concord Wealth Partners lifted its position in GSK by 231.8% during the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company's stock valued at $32,000 after purchasing an additional 547 shares during the last quarter. Ashton Thomas Private Wealth LLC bought a new position in GSK during the second quarter valued at $37,000. Fortitude Family Office LLC bought a new position in GSK during the third quarter valued at $42,000. Finally, PrairieView Partners LLC bought a new position in GSK during the second quarter valued at $47,000. Institutional investors own 15.74% of the company's stock.
GSK stock opened at $33.36 on Thursday. The company has a market capitalization of $69.14 billion, a PE ratio of 21.66, a P/E/G ratio of 1.28 and a beta of 0.66. GSK plc has a 12 month low of $32.83 and a 12 month high of $45.92. The firm's 50-day moving average is $38.46 and its 200 day moving average is $40.49. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.
The business also recently declared a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be paid a $0.3928 dividend. This represents a $1.57 annualized dividend and a yield of 4.71%. The ex-dividend date of this dividend is Friday, November 15th. This is an increase from GSK's previous quarterly dividend of $0.38. GSK's dividend payout ratio (DPR) is currently 99.35%.
Several equities research analysts have recently weighed in on GSK shares. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. Argus raised shares of GSK to a "strong-buy" rating in a research note on Wednesday, August 7th. Barclays raised shares of GSK to a "hold" rating in a research note on Tuesday, August 27th. Guggenheim downgraded shares of GSK from a "buy" rating to a "neutral" rating in a research note on Thursday, October 31st. Finally, Jefferies Financial Group downgraded shares of GSK from a "buy" rating to a "hold" rating and reduced their target price for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Seven research analysts have rated the stock with a hold rating and three have given a strong buy rating to the company. According to MarketBeat.com, GSK currently has a consensus rating of "Moderate Buy" and an average price target of $43.25.
Get Our Latest Stock Report on GSK
In other GSK news, major shareholder Plc Gsk bought 2,791,930 shares of the business's stock in a transaction on Friday, September 27th. The shares were acquired at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the transaction, the insider now owns 16,775,691 shares of the company's stock, valued at approximately $134,205,528. This trade represents a 19.97 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 10.00% of the stock is currently owned by insiders.
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.